In a recent announcement, LumeNXT noted the appointment of Marc Beer as the company’s new Chairman of the Board. LumeNXT is a private company that specializes on developing a surgical illumination product line designed for surgeries that have a minimally invasive approach. The company focuses on pioneering the use of intracavity LED illumination, its illumination platform being used as a mechanism designed to improve workflow efficiency, precision, and also safety via visualization. According to surgeons that have used targeted illumination, they find the technology is able to enhance visualization, precision, and flexibility during operations.
Marc Beer, the newly appointed Chariman of the Board of LumeNXT, has a career in the field of healthcare spanning more than 25 years. He has experience in areas concerning commercialization and development in fields such as pharmaceuticals, biotechnology, devices, and diagnostics. Beer stated that he believes the importance of the company’s illumination platform will continue to increase, as more surgeries are being performed using minimally invasive techniques. He also noted that he is proud to be working with the company’s group of engineers and surgeons, describing them as being accomplished and dedicated, and being responsible for advancing the field of surgical illumination by using the company’s proprietary technology.
LumeNXT’s co-found, Paul Rhyne, also had something to say about the new Chairman of the Board, pointing out that Marc Beer has shown high levels of success in a number of startup companies, as he guided them through multiple growth phases. The co-founder also stated that Beer’s experience when it comes to starting companies and guiding them to profitability is valued at LumeNXT, as the company continues to grow.
Besides his new role at LumeNXT, Marc Beer is also at the helm of Renovia, Inc. a company that he co-founded in August of 2016, where he serves as Chief Executive Officer. The company focuses on discovering and delivering digital therapeutic and diagnostic devices designed to help those who are affected by pelvic floor disorders. In addition, throughout his career spanning a quarter of a century, Beer has been involved with many organizations within the healthcare segment, having various roles.
Beer was the Founding CEO at ViaCell, a role he took in April of 2000. ViaCell was a biotechnology company that focused on umbilical cord blood stem cells, and under Beer’s leadership the company grew to have 300 employees and became a publicly traded company in 2005, before being ultimately acquired by PerkinElmer, 2 years later. During his 7-year stint at ViaCell, Beer was also a member on the board of directors at Erytech Pharma, a biopharmaceutical company. He was also involved with Genzyme during his career, serving as Vice President of Global Marketing, and also with organizations such as Abbott Laboratories and Minerva Neurosciences, among others. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer